StockMacro
Menu

Atossa Therapeutics

$1.59 -68% in 6 monthsMarket cap $15.9M

ATOS on XNAS, Health Care, Atossa Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 37% in one month and 86% in a year, with short interest at 5.3% of shares.

  • BadNet loss $34.7M over 12 months against $20.6M cash

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

Industry
Pharmaceutical preparations (Health Care)
Employees
14
Website
atossatherapeutics.com
Listed
Nasdaq, US
Last results
10 Nov 2026
Next results
expected around 8 Jan 2027 (an estimate: a year ago it reported on 9 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $5.6M.
Quarter to 31 Dec 2021: revenue –, net income -$4.8MQuarter to 31 Mar 2022: revenue –, net income -$4.8MQuarter to 30 Jun 2022: revenue –, net income -$6.7MQuarter to 30 Sep 2022: revenue –, net income -$8.0MQuarter to 31 Dec 2022: revenue –, net income -$7.5MQuarter to 31 Mar 2023: revenue –, net income -$6.3MQuarter to 30 Jun 2023: revenue –, net income -$9.8MQuarter to 30 Sep 2023: revenue –, net income -$6.2MQuarter to 31 Dec 2023: revenue –, net income -$7.8MQuarter to 31 Mar 2024: revenue –, net income -$5.9MQuarter to 30 Jun 2024: revenue –, net income -$6.0MQuarter to 30 Sep 2024: revenue –, net income -$7.2MQuarter to 31 Dec 2024: revenue –, net income -$6.3MQuarter to 31 Mar 2025: revenue –, net income -$6.7MQuarter to 30 Jun 2025: revenue –, net income -$8.4MQuarter to 30 Sep 2025: revenue –, net income -$8.7MQuarter to 31 Dec 2025: revenue –, net income -$10.9MQuarter to 31 Mar 2026: revenue –, net income -$9.6MQuarter to 30 Jun 2026: revenue –, net income -$8.5MQuarter to 30 Sep 2026: revenue –, net income -$5.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $10.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$5.6M
30 Jun 2026–-$8.5M
31 Mar 2026–-$9.6M
31 Dec 2025–-$10.9M
30 Sep 2025–-$8.7M
30 Jun 2025–-$8.4M
31 Mar 2025–-$6.7M
31 Dec 2024–-$6.3M
30 Sep 2024–-$7.2M
30 Jun 2024–-$6.0M
31 Mar 2024–-$5.9M
31 Dec 2023–-$7.8M
30 Sep 2023–-$6.2M
30 Jun 2023–-$9.8M
31 Mar 2023–-$6.3M
31 Dec 2022–-$7.5M
30 Sep 2022–-$8.0M
30 Jun 2022–-$6.7M
31 Mar 2022–-$4.8M
31 Dec 2021–-$4.8M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$34.7M -$30.2M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$3.89 -$2.82
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -96.9% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $20.6M $51.8M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$20.6M (net cash) -$51.8M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $2.18
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.73 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Atossa TherapeuticsATOS (this company) $15.9Mloss–––
LipocineLPCN $16.4Mloss4.4-13%-249%
Shuttle PharmaceuticalsSHPH $16.6Mloss–––
CelularityCELU $15.0Mloss0.80-58%-246%
Context TherapeuticsCNTX $14.7Mloss–––
Pasithea TherapeuticsKTTA $17.6Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+9.4%

35 13F filers vs 32

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

9.7%

971K shares held by 13F filers (30 Sep 2026) of 10.0M outstanding (31 Jul 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

5.3%

527K shares sold short (30 Oct 2026) of 10.0M outstanding (31 Jul 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

7.6

527K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-23%

684K shares sold short in the report before, 527K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

60%

60% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 50%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

5

5 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

5 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Price $1.59 on 20 Nov 2026, -86% over 12 months (12-month range $1.59 to $13.57)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $17K).
Capital spending per quarter. Capital spending $0 in the latest quarter, -100% on a year earlier.
Institutional holders (13F filers). 35 13F filers reported holding it in the latest 13F quarter, -45% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
20 Feb 20268-K and other filingsA major agreement ended
17 Feb 20268-K and other filingsDelisting notice or listing transfer
14 Oct 20258-K and other filingsDirector or officer change
14 Oct 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Aug 20258-K and other filingsDelisting notice or listing transfer
24 Feb 20258-K and other filingsDelisting notice or listing transfer
20 Aug 2024Sharp changeMany funds opening a new position: many funds opening a new position, 25 vs usual 6 (2024-06-30); 2.5x the same period a year earlier
2 Jul 20248-K and other filingsDirector or officer change
2 Jul 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 May 2024Sharp changeShort interest spike: short interest spike, 11.5M vs usual 7.4M (2024-05-15); 1.5x the same period a year earlier
14 May 2024Sharp changeShort interest spike: short interest spike, 11.4M vs usual 7.4M (2024-04-30); 1.4x the same period a year earlier
30 Apr 2024Sharp changeShort interest spike: short interest spike, 12.4M vs usual 7.4M (2024-04-15); 1.5x the same period a year earlier
18 Mar 20248-K and other filingsDelisting notice or listing transfer
12 Mar 20248-K and other filingsDirector or officer change
12 Mar 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Nov 20238-K and other filingsDirector or officer change
6 Oct 20238-K and other filingsDirector or officer change
6 Oct 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Sep 20238-K and other filingsDelisting notice or listing transfer
13 Jul 20238-K and other filingsDelisting notice or listing transfer
23 Jun 20238-K and other filingsDelisting notice or listing transfer
1 Jun 20238-K and other filingsDirector or officer change
1 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 May 20238-K and other filingsChanged its auditor
4 Apr 20238-K and other filingsDelisting notice or listing transfer
7 Oct 20228-K and other filingsDelisting notice or listing transfer
28 Feb 20228-K and other filingsDirector or officer change
28 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Jun 2023: $48K published
Month from 1 Nov 2023: -$32K published
Month from 1 Apr 2024: $44K published
Month from 1 Mar 2025: $7K published
Month from 1 May 2025: $10K published
Capital spending per quarter
Quarter ended 31 Mar 2021: $0; public on 10 May 2022
Quarter ended 31 Mar 2022: $13K; public on 10 May 2022
Quarter ended 31 Dec 2022: $8K; public on 23 Mar 2023
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $13K; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $1K; public on 14 Nov 2023
Quarter ended 31 Mar 2024: $6K; public on 14 May 2024
Quarter ended 30 Jun 2024: $3K, -77% on a year earlier; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $10K, +900% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Mar 2025: $9K, +50% on a year earlier; public on 14 May 2025
Quarter ended 30 Sep 2025: $7K, -30% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $7K; public on 26 Mar 2026
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 9 May 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 11 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 81; public on 14 Feb 2022
31 Mar 2022 report: 77; public on 16 May 2022
30 Jun 2022 report: 67; public on 15 Aug 2022
30 Sep 2022 report: 50; public on 14 Nov 2022
31 Dec 2022 report: 43; public on 14 Feb 2023
31 Mar 2023 report: 39; public on 15 May 2023
30 Jun 2023 report: 45; public on 14 Aug 2023
30 Sep 2023 report: 46; public on 14 Nov 2023
31 Dec 2023 report: 45; public on 14 Feb 2024
31 Mar 2024 report: 63; public on 15 May 2024
30 Jun 2024 report: 73; public on 14 Aug 2024
30 Sep 2024 report: 82; public on 14 Nov 2024
31 Dec 2024 report: 86; public on 14 Feb 2025
31 Mar 2025 report: 81; public on 15 May 2025
30 Jun 2025 report: 80; public on 14 Aug 2025
30 Sep 2025 report: 64; public on 14 Nov 2025
31 Dec 2025 report: 64; public on 17 Feb 2026
31 Mar 2026 report: 31; public on 15 May 2026
30 Jun 2026 report: 32; public on 14 Aug 2026
30 Sep 2026 report: 35; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 35 (30 Sep 2026), 45% below its normal reading of 64; higher than 63% of its own history.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $17K).
  • Capital spending per quarter: Capital spending $0 in the latest quarter, -100% on a year earlier.
  • Institutional holders (13F filers): 35 13F filers reported holding it in the latest 13F quarter, -45% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 15 insider trades

No trades in the last 90 days; the latest was filed 22 May 2025. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
22 May 2025Steven C QuayPresident & CEOBuy11,239$0.88$10KForm 4
28 Mar 2025H. Lawrence RemmelDirectorBuy10,000$0.70$7KForm 4
11 Apr 2024Jonathan FinnDirectorBuy25,000$1.77$44KForm 4
17 Nov 2023Gregory L WeaverFormer EVP, CFO, & DirectorSell50,000$0.65$32KForm 4
20 Jun 2023Gregory L WeaverEVP & CFOBuy50,000$0.97$48KForm 4
7 Jul 2021Gregory L WeaverDirectorSellafter exercising options107,497$5.58$600KForm 4
16 Nov 2017Kyle GuseCFO, Gen Counsel and SecretaryBuy10,000$0.34$3KForm 4
18 Apr 2017H. Lawrence RemmelDirectorBuy2,500$0.63$2KForm 4

35 institutions reported shares at the end of Q3 2026, 10% of the shares outstanding; 8 opened a position, 7 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Vanguard Capital Management LLC362K3.62%$705KNo change
BlackRock, Inc.169K1.69%$329K+4,263+2.6%
Renaissance Technologies LLC110K1.10%$214K-22K-17%
Geode Capital Management, LLC96K0.96%$186K+3,195+3.5%
Vanguard Fiduciary Trust Co53K0.53%$103KNo change
State Street Corp40K0.40%$78KNo change
UBS Group AG31K0.31%$59K-52K-63%
Ameriprise Financial Inc27K0.27%$53K-231K-89%
Susquehanna International Group, LLP22K0.22%$42K+5,939+38%
Northern Trust Corp20K0.20%$39K-36-0.2%

Company events

All 62 company events

In 12 months: 3 major agreements, 1 delisting notice, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
9 Oct 2026Signed a major agreementSame filing: changed shareholder rights8-K
11 Jun 2026Signed a major agreement8-K
20 Feb 2026Signed a major agreement; A major agreement ended8-K
17 Feb 2026Delisting notice or listing transfer8-K
14 Oct 2025Director or officer change8-K
21 Aug 2025Delisting notice or listing transfer8-K
24 Feb 2025Delisting notice or listing transfer8-K
19 Nov 2024Signed a major agreement8-K

Reported lobbying spend: $40K in Q1 2021, $40K in Q4 2020. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Mar 2021EndedDesimone Consulting, LLCfor Atossa Therapeutics, Inc.Efforts to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on COVID-19.MEDFiling
11 May 2020NewDesimone Consulting, LLCfor Atossa Therapeutics, Inc.Efforts to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on COVID-19.MEDFiling
23 Dec 2015EndedDesimone Consulting, LLCfor Atossa Genetics, Inc.Issues related to healthcare, research and development, and the drug approval process.MEDFiling
8 Jun 2015NewDesimone Consulting, LLCfor Atossa Genetics, Inc.Issues related to healthcare, research and development, and the drug approval process.Health issues, MEDFiling

The 5 newest of 50 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

18 May 2021confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Atossa Therapeutics (ATOS): had 20.5M shares sold short in the 30 Jun 2021 report, 106× the same report last year, while it saw 51 13F filers open a new position in the quarter ended 30 Jun 2021, 13× the same quarter last year. Two unrelated kinds of activity within 112 days.

  • Short interest and volume: Short interest spike, became public on 27 Apr 2021
  • Institutional holdings: Many funds opening a new position, became public on 17 May 2021
  • Short interest and volume: Short interest spike, became public on 12 May 2021
  • Short interest and volume: Short interest spike, became public on 26 May 2021
  • Short interest and volume: Short interest spike, became public on 10 Jun 2021
  • Short interest and volume: Short interest spike, became public on 26 Jun 2021
  • Short interest and volume: Short interest spike, became public on 13 Jul 2021
  • Short interest and volume: Short interest spike, became public on 27 Jul 2021
  • Institutional holdings: Many funds opening a new position, became public on 16 Aug 2021
2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M2021-05-28: 13.8M2021-06-15: 16.5M2021-06-30: 20.5M
The 30 Jun 2021 report against the 24 reports before it. this reportearliernormal: 1.7M
See the evidence (9 changes)

Short interest and volume: Short interest spike became public on 27 Apr 2021

Atossa Therapeutics had 10.5M shares sold short in the 15 Apr 2021 report, 44× the same report last year.

This period
10.5M (the 15 Apr 2021 report)
Normal report (median of 24 earlier)
256K
Typical spread (median absolute deviation)
80K
How far from its usual level
+85.7
Same report last year
239K
History used
1,203 days
2020-04-15: 239K2020-04-30: 256K2020-05-15: 208K2020-05-29: 306K2020-06-15: 235K2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M
the 15 Apr 2021 report24 earlier reportsnormal: 256K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 17 May 2021

Atossa Therapeutics saw 30 13F filers open a new position in the quarter ended 31 Mar 2021, 15× the same quarter last year.

This period
30 (the quarter ended 31 Mar 2021)
Normal quarter (median of 8 earlier)
3
Typical spread (median absolute deviation)
1
How far from its usual level
+9.0
Same quarter last year
2
History used
2,739 days
2019-03-31: 22019-06-30: 42019-09-30: 42019-12-31: 22020-03-31: 22020-06-30: 42020-09-30: 122020-12-31: 22021-03-31: 30
the quarter ended 31 Mar 20218 earlier quartersnormal: 3

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 12 May 2021

Atossa Therapeutics had 13.3M shares sold short in the 30 Apr 2021 report, 52× the same report last year.

This period
13.3M (the 30 Apr 2021 report)
Normal report (median of 24 earlier)
273K
Typical spread (median absolute deviation)
102K
How far from its usual level
+85.7
Same report last year
256K
History used
1,218 days
2020-04-30: 256K2020-05-15: 208K2020-05-29: 306K2020-06-15: 235K2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M
the 30 Apr 2021 report24 earlier reportsnormal: 273K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 May 2021

Atossa Therapeutics had 13.4M shares sold short in the 14 May 2021 report, 64× the same report last year.

This period
13.4M (the 14 May 2021 report)
Normal report (median of 24 earlier)
298K
Typical spread (median absolute deviation)
138K
How far from its usual level
+64.1
Same report last year
208K
History used
1,232 days
2020-05-15: 208K2020-05-29: 306K2020-06-15: 235K2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M
the 14 May 2021 report24 earlier reportsnormal: 298K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Jun 2021

Atossa Therapeutics had 13.8M shares sold short in the 28 May 2021 report, 45× the same report last year.

This period
13.8M (the 28 May 2021 report)
Normal report (median of 24 earlier)
375K
Typical spread (median absolute deviation)
225K
How far from its usual level
+40.2
Same report last year
306K
History used
1,246 days
2020-05-29: 306K2020-06-15: 235K2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M2021-05-28: 13.8M
the 28 May 2021 report24 earlier reportsnormal: 375K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Jun 2021

Atossa Therapeutics had 16.5M shares sold short in the 15 Jun 2021 report, 70× the same report last year.

This period
16.5M (the 15 Jun 2021 report)
Normal report (median of 24 earlier)
554K
Typical spread (median absolute deviation)
403K
How far from its usual level
+26.7
Same report last year
235K
History used
1,264 days
2020-06-15: 235K2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M2021-05-28: 13.8M2021-06-15: 16.5M
the 15 Jun 2021 report24 earlier reportsnormal: 554K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Jul 2021

Atossa Therapeutics had 20.5M shares sold short in the 30 Jun 2021 report, 106× the same report last year.

This period
20.5M (the 30 Jun 2021 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+8.0
Same report last year
194K
History used
1,279 days
2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M2021-05-28: 13.8M2021-06-15: 16.5M2021-06-30: 20.5M
the 30 Jun 2021 report24 earlier reportsnormal: 1.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Jul 2021

Atossa Therapeutics had 25.7M shares sold short in the 15 Jul 2021 report, 152× the same report last year.

This period
25.7M (the 15 Jul 2021 report)
Normal report (median of 24 earlier)
4.3M
Typical spread (median absolute deviation)
4.1M
How far from its usual level
+3.5
Same report last year
169K
History used
1,294 days
2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M2021-05-28: 13.8M2021-06-15: 16.5M2021-06-30: 20.5M2021-07-15: 25.7M
the 15 Jul 2021 report24 earlier reportsnormal: 4.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 16 Aug 2021

Atossa Therapeutics saw 51 13F filers open a new position in the quarter ended 30 Jun 2021, 13× the same quarter last year.

This period
51 (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
4
Typical spread (median absolute deviation)
2
How far from its usual level
+15.7
Same quarter last year
4
History used
2,830 days
2019-06-30: 42019-09-30: 42019-12-31: 22020-03-31: 22020-06-30: 42020-09-30: 122020-12-31: 22021-03-31: 302021-06-30: 51
the quarter ended 30 Jun 20218 earlier quartersnormal: 4

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 20 Feb 2026Filings record

    A major agreement ended

  2. 17 Feb 2026Filings record

    Delisting notice or listing transfer

  3. 14 Oct 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 14 Oct 2025Filings record

    Director or officer change

  5. 21 Aug 2025Filings record

    Delisting notice or listing transfer

  6. 23 May 2025Insiders record

    QUAY STEVEN C (President & CEO) bought 11,239 shares of ATOS ($9,890) (dated 22 May 2025)

  7. 29 Mar 2025Insiders record

    Remmel H. Lawrence (director) bought 10,000 shares of ATOS ($7,000) (dated 28 Mar 2025)

  8. 24 Feb 2025Filings record

    Delisting notice or listing transfer

  9. 14 Aug 2024Institutional holdings change

    saw 25 13F filers open a new position in the quarter ended 30 Jun 2024, 2.5× the same quarter last year.

    Same quarter last year: 10; its normal quarter is 6.

    See the evidence
    This period
    25 (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    6
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +3.7
    Same quarter last year
    10
    History used
    3,926 days
    2022-06-30: 142022-09-30: 52022-12-31: 42023-03-31: 22023-06-30: 102023-09-30: 72023-12-31: 32024-03-31: 192024-06-30: 25
    the quarter ended 30 Jun 20248 earlier quartersnormal: 6

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  10. 2 Jul 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 2 Jul 2024Filings record

    Director or officer change

  12. 25 May 2024Short interest and volume change

    had 11.5M shares sold short in the 15 May 2024 report, 1.5× the same report last year.

    Same report last year: 7.8M; its normal report is 7.4M.

    See the evidence
    This period
    11.5M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    7.4M
    Typical spread (median absolute deviation)
    773K
    How far from its usual level
    +3.6
    Same report last year
    7.8M
    History used
    2,329 days
    2023-05-15: 7.8M2023-05-31: 7.5M2023-06-15: 7.3M2023-06-30: 7.8M2023-07-14: 8.7M2023-07-31: 8.5M2023-08-15: 8.3M2023-08-31: 8.2M2023-09-15: 8.0M2023-09-29: 7.3M2023-10-13: 7.0M2023-10-31: 6.7M2023-11-15: 6.4M2023-11-30: 6.2M2023-12-15: 6.3M2023-12-29: 6.4M2024-01-12: 7.0M2024-01-31: 6.8M2024-02-15: 7.0M2024-02-29: 7.2M2024-03-15: 8.5M2024-03-28: 10.6M2024-04-15: 12.4M2024-04-30: 11.4M2024-05-15: 11.5M
    the 15 May 2024 report24 earlier reportsnormal: 7.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 10 May 2024Short interest and volume change

    had 11.4M shares sold short in the 30 Apr 2024 report, 1.4× the same report last year.

    Same report last year: 8.1M; its normal report is 7.4M.

    See the evidence
    This period
    11.4M (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    7.4M
    Typical spread (median absolute deviation)
    711K
    How far from its usual level
    +3.8
    Same report last year
    8.1M
    History used
    2,314 days
    2023-04-28: 8.1M2023-05-15: 7.8M2023-05-31: 7.5M2023-06-15: 7.3M2023-06-30: 7.8M2023-07-14: 8.7M2023-07-31: 8.5M2023-08-15: 8.3M2023-08-31: 8.2M2023-09-15: 8.0M2023-09-29: 7.3M2023-10-13: 7.0M2023-10-31: 6.7M2023-11-15: 6.4M2023-11-30: 6.2M2023-12-15: 6.3M2023-12-29: 6.4M2024-01-12: 7.0M2024-01-31: 6.8M2024-02-15: 7.0M2024-02-29: 7.2M2024-03-15: 8.5M2024-03-28: 10.6M2024-04-15: 12.4M2024-04-30: 11.4M
    the 30 Apr 2024 report24 earlier reportsnormal: 7.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 25 Apr 2024Short interest and volume change

    had 12.4M shares sold short in the 15 Apr 2024 report, 1.5× the same report last year.

    Same report last year: 8.3M; its normal report is 7.4M.

    See the evidence
    This period
    12.4M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    7.4M
    Typical spread (median absolute deviation)
    711K
    How far from its usual level
    +4.7
    Same report last year
    8.3M
    History used
    2,299 days
    2023-04-14: 8.3M2023-04-28: 8.1M2023-05-15: 7.8M2023-05-31: 7.5M2023-06-15: 7.3M2023-06-30: 7.8M2023-07-14: 8.7M2023-07-31: 8.5M2023-08-15: 8.3M2023-08-31: 8.2M2023-09-15: 8.0M2023-09-29: 7.3M2023-10-13: 7.0M2023-10-31: 6.7M2023-11-15: 6.4M2023-11-30: 6.2M2023-12-15: 6.3M2023-12-29: 6.4M2024-01-12: 7.0M2024-01-31: 6.8M2024-02-15: 7.0M2024-02-29: 7.2M2024-03-15: 8.5M2024-03-28: 10.6M2024-04-15: 12.4M
    the 15 Apr 2024 report24 earlier reportsnormal: 7.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 12 Apr 2024Insiders record

    Finn Jonathan (director) bought 25,000 shares of ATOS ($44,250) (dated 11 Apr 2024)

  16. 18 Mar 2024Filings record

    Delisting notice or listing transfer

  17. 12 Mar 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 12 Mar 2024Filings record

    Director or officer change

  19. 9 Nov 2023Filings record

    Director or officer change

  20. 6 Oct 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 6 Oct 2023Filings record

    Director or officer change

  22. 28 Sep 2023Filings record

    Delisting notice or listing transfer

  23. 13 Jul 2023Filings record

    Delisting notice or listing transfer

  24. 23 Jun 2023Filings record

    Delisting notice or listing transfer

  25. 21 Jun 2023Insiders record

    WEAVER GREGORY L (EVP & CFO) bought 50,000 shares of ATOS ($48,500) (dated 20 Jun 2023)

  26. 1 Jun 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 1 Jun 2023Filings record

    Director or officer change

  28. 22 May 2023Filings record

    Changed its auditor

  29. 4 Apr 2023Filings record

    Delisting notice or listing transfer

  30. 7 Oct 2022Filings record

    Delisting notice or listing transfer

  31. 28 Feb 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 28 Feb 2022Filings record

    Director or officer change

  33. 16 Aug 2021Institutional holdings change

    saw 51 13F filers open a new position in the quarter ended 30 Jun 2021, 13× the same quarter last year.

    Same quarter last year: 4; its normal quarter is 4.

    See the evidence
    This period
    51 (the quarter ended 30 Jun 2021)
    Normal quarter (median of 8 earlier)
    4
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +15.7
    Same quarter last year
    4
    History used
    2,830 days
    2019-06-30: 42019-09-30: 42019-12-31: 22020-03-31: 22020-06-30: 42020-09-30: 122020-12-31: 22021-03-31: 302021-06-30: 51
    the quarter ended 30 Jun 20218 earlier quartersnormal: 4

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  34. 27 Jul 2021Short interest and volume change

    had 25.7M shares sold short in the 15 Jul 2021 report, 152× the same report last year.

    Same report last year: 169K; its normal report is 4.3M.

    See the evidence
    This period
    25.7M (the 15 Jul 2021 report)
    Normal report (median of 24 earlier)
    4.3M
    Typical spread (median absolute deviation)
    4.1M
    How far from its usual level
    +3.5
    Same report last year
    169K
    History used
    1,294 days
    2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M2021-05-28: 13.8M2021-06-15: 16.5M2021-06-30: 20.5M2021-07-15: 25.7M
    the 15 Jul 2021 report24 earlier reportsnormal: 4.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 13 Jul 2021Short interest and volume change

    had 20.5M shares sold short in the 30 Jun 2021 report, 106× the same report last year.

    Same report last year: 194K; its normal report is 1.7M.

    See the evidence
    This period
    20.5M (the 30 Jun 2021 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +8.0
    Same report last year
    194K
    History used
    1,279 days
    2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M2021-05-28: 13.8M2021-06-15: 16.5M2021-06-30: 20.5M
    the 30 Jun 2021 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 26 Jun 2021Short interest and volume change

    had 16.5M shares sold short in the 15 Jun 2021 report, 70× the same report last year.

    Same report last year: 235K; its normal report is 554K.

    See the evidence
    This period
    16.5M (the 15 Jun 2021 report)
    Normal report (median of 24 earlier)
    554K
    Typical spread (median absolute deviation)
    403K
    How far from its usual level
    +26.7
    Same report last year
    235K
    History used
    1,264 days
    2020-06-15: 235K2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M2021-05-28: 13.8M2021-06-15: 16.5M
    the 15 Jun 2021 report24 earlier reportsnormal: 554K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 10 Jun 2021Short interest and volume change

    had 13.8M shares sold short in the 28 May 2021 report, 45× the same report last year.

    Same report last year: 306K; its normal report is 375K.

    See the evidence
    This period
    13.8M (the 28 May 2021 report)
    Normal report (median of 24 earlier)
    375K
    Typical spread (median absolute deviation)
    225K
    How far from its usual level
    +40.2
    Same report last year
    306K
    History used
    1,246 days
    2020-05-29: 306K2020-06-15: 235K2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M2021-05-28: 13.8M
    the 28 May 2021 report24 earlier reportsnormal: 375K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 4 Jun 2021Lobbying record

    ATOSSA THERAPEUTICS, INC.: lobbying engagement terminated (DESIMONE CONSULTING, LLC) (dated 31 Mar 2021)

  39. 26 May 2021Short interest and volume change

    had 13.4M shares sold short in the 14 May 2021 report, 64× the same report last year.

    Same report last year: 208K; its normal report is 298K.

    See the evidence
    This period
    13.4M (the 14 May 2021 report)
    Normal report (median of 24 earlier)
    298K
    Typical spread (median absolute deviation)
    138K
    How far from its usual level
    +64.1
    Same report last year
    208K
    History used
    1,232 days
    2020-05-15: 208K2020-05-29: 306K2020-06-15: 235K2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M
    the 14 May 2021 report24 earlier reportsnormal: 298K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 18 May 2021several at once

    had 20.5M shares sold short in the 30 Jun 2021 report, 106× the same report last year, while it saw 51 13F filers open a new position in the quarter ended 30 Jun 2021, 13× the same quarter last year. Two unrelated kinds of activity within 112 days.

    See the evidence (9 changes)

    Short interest and volume: Short interest spike became public on 27 Apr 2021

    Atossa Therapeutics had 10.5M shares sold short in the 15 Apr 2021 report, 44× the same report last year.

    This period
    10.5M (the 15 Apr 2021 report)
    Normal report (median of 24 earlier)
    256K
    Typical spread (median absolute deviation)
    80K
    How far from its usual level
    +85.7
    Same report last year
    239K
    History used
    1,203 days
    2020-04-15: 239K2020-04-30: 256K2020-05-15: 208K2020-05-29: 306K2020-06-15: 235K2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M
    the 15 Apr 2021 report24 earlier reportsnormal: 256K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 17 May 2021

    Atossa Therapeutics saw 30 13F filers open a new position in the quarter ended 31 Mar 2021, 15× the same quarter last year.

    This period
    30 (the quarter ended 31 Mar 2021)
    Normal quarter (median of 8 earlier)
    3
    Typical spread (median absolute deviation)
    1
    How far from its usual level
    +9.0
    Same quarter last year
    2
    History used
    2,739 days
    2019-03-31: 22019-06-30: 42019-09-30: 42019-12-31: 22020-03-31: 22020-06-30: 42020-09-30: 122020-12-31: 22021-03-31: 30
    the quarter ended 31 Mar 20218 earlier quartersnormal: 3

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 12 May 2021

    Atossa Therapeutics had 13.3M shares sold short in the 30 Apr 2021 report, 52× the same report last year.

    This period
    13.3M (the 30 Apr 2021 report)
    Normal report (median of 24 earlier)
    273K
    Typical spread (median absolute deviation)
    102K
    How far from its usual level
    +85.7
    Same report last year
    256K
    History used
    1,218 days
    2020-04-30: 256K2020-05-15: 208K2020-05-29: 306K2020-06-15: 235K2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M
    the 30 Apr 2021 report24 earlier reportsnormal: 273K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 May 2021

    Atossa Therapeutics had 13.4M shares sold short in the 14 May 2021 report, 64× the same report last year.

    This period
    13.4M (the 14 May 2021 report)
    Normal report (median of 24 earlier)
    298K
    Typical spread (median absolute deviation)
    138K
    How far from its usual level
    +64.1
    Same report last year
    208K
    History used
    1,232 days
    2020-05-15: 208K2020-05-29: 306K2020-06-15: 235K2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M
    the 14 May 2021 report24 earlier reportsnormal: 298K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Jun 2021

    Atossa Therapeutics had 13.8M shares sold short in the 28 May 2021 report, 45× the same report last year.

    This period
    13.8M (the 28 May 2021 report)
    Normal report (median of 24 earlier)
    375K
    Typical spread (median absolute deviation)
    225K
    How far from its usual level
    +40.2
    Same report last year
    306K
    History used
    1,246 days
    2020-05-29: 306K2020-06-15: 235K2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M2021-05-28: 13.8M
    the 28 May 2021 report24 earlier reportsnormal: 375K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Jun 2021

    Atossa Therapeutics had 16.5M shares sold short in the 15 Jun 2021 report, 70× the same report last year.

    This period
    16.5M (the 15 Jun 2021 report)
    Normal report (median of 24 earlier)
    554K
    Typical spread (median absolute deviation)
    403K
    How far from its usual level
    +26.7
    Same report last year
    235K
    History used
    1,264 days
    2020-06-15: 235K2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M2021-05-28: 13.8M2021-06-15: 16.5M
    the 15 Jun 2021 report24 earlier reportsnormal: 554K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 13 Jul 2021

    Atossa Therapeutics had 20.5M shares sold short in the 30 Jun 2021 report, 106× the same report last year.

    This period
    20.5M (the 30 Jun 2021 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +8.0
    Same report last year
    194K
    History used
    1,279 days
    2020-06-30: 194K2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M2021-05-28: 13.8M2021-06-15: 16.5M2021-06-30: 20.5M
    the 30 Jun 2021 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 27 Jul 2021

    Atossa Therapeutics had 25.7M shares sold short in the 15 Jul 2021 report, 152× the same report last year.

    This period
    25.7M (the 15 Jul 2021 report)
    Normal report (median of 24 earlier)
    4.3M
    Typical spread (median absolute deviation)
    4.1M
    How far from its usual level
    +3.5
    Same report last year
    169K
    History used
    1,294 days
    2020-07-15: 169K2020-07-31: 178K2020-08-14: 256K2020-08-31: 204K2020-09-15: 132K2020-09-30: 204K2020-10-15: 173K2020-10-30: 200K2020-11-13: 290K2020-11-30: 445K2020-12-15: 2.8M2020-12-31: 663K2021-01-15: 8.4M2021-01-29: 9.2M2021-02-12: 5.8M2021-02-26: 7.1M2021-03-15: 6.6M2021-03-31: 10.0M2021-04-15: 10.5M2021-04-30: 13.3M2021-05-14: 13.4M2021-05-28: 13.8M2021-06-15: 16.5M2021-06-30: 20.5M2021-07-15: 25.7M
    the 15 Jul 2021 report24 earlier reportsnormal: 4.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 16 Aug 2021

    Atossa Therapeutics saw 51 13F filers open a new position in the quarter ended 30 Jun 2021, 13× the same quarter last year.

    This period
    51 (the quarter ended 30 Jun 2021)
    Normal quarter (median of 8 earlier)
    4
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +15.7
    Same quarter last year
    4
    History used
    2,830 days
    2019-06-30: 42019-09-30: 42019-12-31: 22020-03-31: 22020-06-30: 42020-09-30: 122020-12-31: 22021-03-31: 302021-06-30: 51
    the quarter ended 30 Jun 20218 earlier quartersnormal: 4

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Showing the newest 40 of 94 entries; narrow the window or the kind of data to see older ones.

Not listed: 134 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001488039
Ticker
ATOS
Domain
atossatherapeutics.com
Hq location
WA|SEATTLE|98107 (1 unverified)
Lobbying client
atossa genetics, atossa therapeutics
Name
atos-ex21_1.htm, Atossa Genetics AUS Pty Ltd, ATOSSA GENETICS INC, Atossa Genetics UK Ltd and 2 more
Wikidata
Q107517747
  • Federal lobbying disclosures (LDA)4 records, 21 data points8 Jun 2015 to 31 Mar 2021
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)176 records29 Jan 2016 to 10 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)791 data points27 Apr 2009 to 30 Sep 2026
  • SEC Form 4 insider transactions15 records, 48 data points21 Jan 2016 to 22 May 2025
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026